BIO-Europe, November 11-13, 2019, Hamburg, Germany
At BIO-Europe, Anthony Hoerning, Senior Business Advisor to ImmunoMet, will be available for private meetings on November 11-13 to discuss potential collaboration, partnering and licensing opportunities with a focus on the Company’s fibrosis asset.  Visit this link for more information on partnering at BIO-Europe: https://ebdgroup.knect365.com/bioeurope/partnering. 

About BIO Investor Forum
The BIO Investor Forum is an international biotech investor conference focused on venture-stage growth, as well as emerging public companies. The event features expert-led panel discussions, fireside chats, public and venture-stage company presentations, BIO One-on-One Partnering™ meetings and a premier opportunity to network with industry executives and investors focused exclusively on life sciences.

About BIO-Europe
BIO-Europe is Europe’s largest life science partnering conference for the biotechnology industry. It brings together over 2,300 companies from over 60 countries offering high profile workshops, panels, company pitches, and one-on-one meetings. BIO-Europe offers countless opportunities to engage with global life science partners.

About ImmunoMet Therapeutics
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is an OXPHOS inhibitor with demonstrated impressive in-vivo efficacy in resistant solid tumors. IM156 is currently in Phase 1 with a good safety profile and is expected to progress into Phase 2 in 2020. ImmunoMet has initiated a second program in fibrosis and owns a large library of biguanides with the potential to develop, or partner, new products. The company was founded in 2015, is headquartered in the Houston JLABs near MD Anderson, and has raised $19M to date.  For more information about the company, please visit www.immunomet.com.